BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $72,830,383 | -16.7% | 1,069,934 | -0.1% | 1.54% | -11.0% |
| Q2 2023 | $87,467,945 | +10.2% | 1,071,517 | +0.1% | 1.72% | +6.6% |
| Q1 2023 | $79,402,344 | -9.6% | 1,070,257 | +1.0% | 1.62% | -18.0% |
| Q4 2022 | $87,811,360 | +16.1% | 1,059,500 | +297.7% | 1.97% | +12.9% |
| Q3 2022 | $75,656,000 | -14.8% | 266,393 | +4.0% | 1.75% | -14.5% |
| Q2 2022 | $88,801,000 | -20.4% | 256,177 | -0.6% | 2.04% | -5.2% |
| Q1 2022 | $111,574,000 | -16.5% | 257,652 | -0.3% | 2.16% | +0.0% |
| Q4 2021 | $133,694,000 | +4.4% | 258,427 | -2.2% | 2.16% | -0.6% |
| Q3 2021 | $128,076,000 | -19.4% | 264,307 | -25.1% | 2.17% | -16.2% |
| Q2 2021 | $158,933,000 | +16.1% | 352,981 | -1.5% | 2.59% | +10.8% |
| Q1 2021 | $136,893,000 | +7.0% | 358,424 | -11.1% | 2.34% | +7.7% |
| Q4 2020 | $127,959,000 | +32.0% | 402,958 | +3.0% | 2.17% | +8.4% |
| Q3 2020 | $96,958,000 | -4.0% | 391,385 | +2.3% | 2.00% | -8.5% |
| Q2 2020 | $101,010,000 | +43.2% | 382,512 | +2.8% | 2.19% | +9.0% |
| Q1 2020 | $70,542,000 | +270.2% | 372,013 | +82.6% | 2.01% | +260.1% |
| Q3 2014 | $19,055,000 | – | 203,693 | – | 0.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |